NCT03566199View on ClinicalTrials.gov

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
DRUG

Panobinostat Nanoparticle Formulation MTX110

Given IT

DRUG

Convection-Enhanced Delivery (CED)

Undergo CED

Trial Locations (1)

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Midatech Pharma US Inc.

INDUSTRY

collaborator

Pacific Pediatric Neuro-Oncology Consortium

OTHER

lead

Sabine Mueller, MD, PhD

OTHER

NCT03566199 - MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma | Biotech Hunter | Biotech Hunter